Market Cap | 372.50M | P/E | - | EPS this Y | 145.50% | Ern Qtrly Grth | - |
Income | -54.86M | Forward P/E | 19.08 | EPS next Y | 20.40% | 50D Avg Chg | 23.00% |
Sales | 453.38M | PEG | 0.45 | EPS past 5Y | - | 200D Avg Chg | 51.00% |
Dividend | N/A | Price/Book | 0.50 | EPS next 5Y | 64.40% | 52W High Chg | -31.00% |
Recommedations | 2.70 | Quick Ratio | 1.06 | Shares Outstanding | 27.57M | 52W Low Chg | 180.00% |
Insider Own | 1.93% | ROA | -0.36% | Shares Float | 24.29M | Beta | 1.99 |
Inst Own | 92.90% | ROE | -9.78% | Shares Shorted/Prior | 550.91K/719.81K | Price | 14.12 |
Gross Margin | 63.11% | Profit Margin | -77.58% | Avg. Volume | 304,146 | Target Price | 20.37 |
Oper. Margin | -1.43% | Earnings Date | Aug 1 | Volume | 530,842 | Change | 0.21% |
ZimVie Inc., together with its subsidiaries, develops, manufactures, and markets a portfolio of products and solutions designed to support dental tooth replacement and restoration procedures worldwide. It operates through The Dental Segment. The company offers dental implant systems; biomaterials; prosthetic and abutment products, surgical instrumentation, and kits; and patient-specific restorative solutions, such as abutments, bars, implant bridges, and hybrid restorations under the BellaTek brand name. It provides bone grafts, barrier membranes, and collagen wound care products; virtual treatment planning services, guided surgery solutions, CAD/CAM workflow systems, and intra-oral scanners; and Implant Concierge, a web-based treatment planning and surgery guide service. The company sells its products to oral surgeons, dental specialists, general dentists, dental laboratories, and other dental organizations, including DSOs, as well as educational, medical, and governmental entities, hospitals, and surgery centers through direct sales representatives, agents, and distributors. ZimVie Inc. was incorporated in 2021 and is headquartered in Palm Beach Gardens, Florida with additional facilities around the globe.
Needham | Buy | Aug 2, 24 |
Needham | Buy | Jun 25, 24 |
Needham | Buy | May 16, 24 |
Needham | Hold | May 9, 24 |
Needham | Hold | Apr 11, 24 |
Barclays | Underweight | Mar 5, 24 |
Barclays | Underweight | Jan 4, 24 |
JP Morgan | Neutral | Dec 20, 23 |
Needham | Hold | Nov 16, 23 |